|
Untitled Document


|
Symptom Management: CINV
New Management Strategies for CINV

Coming Soon!
Supported by an unrestricted educational grant from Merck, Inc.
Clinical experts will discuss new strategies for managing CINV, including
recent data and evidence-based guidelines. Interactive vignettes and case
studies will set the stage for a faculty led discussion of important issues
such as quality of life, evaluating risk, uncontrolled CINV, and access
to care.
CINV: Affecting Pathways, Optimizing Outcomes: Breakthrough, Delayed, Refractory CINV

0.9 Contact Hours
Expiration:
1/30/2009
This newsletter is supported by an unrestricted educational grant from Solvay Pharmaceuticals. |
| Here is the latest information about the management of breakthrough, delayed and refractory CINV written by clinical experts. This newsletter provides risk factor assessment and treatment information for this difficult condition. In addition, case studies are presented with questions and answers for an immediate understanding of how this information can be applied to specific situations.
CNE ID # 06-1303-01
Download
PDF | Take
CNE test | Order
Material | Get
Podcasts
|
Applying New Data to Manage CINV:
Achieving optimal outcomes through a comprehensive care model

2.5 Contact Hours
Expiration: 10/01/2008
This webcast is supported by an unrestricted educational grant from
Merck & Co., Inc. |
| Clinical experts will review the newest
data and evidence-based guidelines for managing CINV through
interactive case studies that focus on a team-care approach.
This webcast will provide an interactive case study discussion where
clinical experts will review the newest data and evidence-based
guidelines for managing CINV. The panel will focus on a team-care
approach, providing perspectives of the nurse, physician, and pharmacist.
The faculty will discuss ways to optimize patient outcomes in both
the inpatient and outpatient settings.
CNE ID #06-740-01
View
Webcast | Take
CNE test
|
|